11AM Hour: Revolution Medicines CEO on Drug Approval, Nvidia Rallies on Earnings & Synopsys CEO 8/27/26

Key takeaways

Nvidia's earnings guidance and ecosystem position continue to drive the tech sector rally, with supply constraints viewed as a temporary bottleneck.
Google’s new flexible pricing models in AI services aim to capture more enterprise spending amid rising AI budgets, challenging competitors like Microsoft and Anthropic.
Revolution Medicines received FDA approval for RazonQ, a significant breakthrough for pancreatic cancer treatment, with potential implications for other RAS-driven cancers.
Federal Reserve’s stance on interest rates remains cautious, with inflation expectations and geopolitical risks considered critical factors influencing policy decisions.

Summary

Market and Tech Sector Highlights

The episode opens with a focus on the rally in shares driven by Nvidia's strong earnings guidance, emphasizing the tech sector's performance within the wider market. Nvidia's role as a critical component in AI infrastructure is highlighted, including insights from CEO Jensen Huang about its fungibility and ecosystem. Analyst Jim Schneider discusses Nvidia’s sales forecasts, supply chain constraints, and the company's dividend and buyback plans, reinforcing Nvidia's leadership and attractive valuation despite sector-wide pressures.

AI Development, Pricing, and Competition

The conversation shifts to the competitive landscape of AI services, with Google introducing new pay-as-you-go pricing and discounts to attract enterprise clients amidst rising AI budgets that have exceeded expectations. The discussion points out the intense competition between Google, Microsoft, Anthropic, and others, with a focus on pricing strategies, market share, and the potential for Google to leverage its financial strength to gain a greater share of AI deployment budgets.

Revolution Medicines and Drug Innovation

Revolution Medicines CEO Dr. Mark Goldsmith discusses FDA approval for RazonQ, a targeted pancreatic cancer medication that significantly extends survival at a high cost but with a strong value proposition. The conversation covers the drug's potential to change treatment paradigms, its applicability to other cancers involving RAS proteins, and the company’s efforts in research, development, and future pipeline prospects. The impact of AI in accelerating drug discovery is briefly touched upon, along with the importance of access and insurance coverage for new medicines.

Federal Reserve and Inflation Outlook

Former Minneapolis Fed President Gary Stern provides his perspective on the likelihood of upcoming Federal Reserve rate hikes, emphasizing the importance of inflation expectations and bond market signals. He warns about geopolitical and tariff-related risks that could alter inflation prospects and discusses policy options to address supply-side constraints to control inflation without immediate rate increases.

Show notes

Revolution Medicines CEO Dr. Mark Goldsmith joins after the company received FDA approval for its pancreatic cancer pill that's priced at roughly $40,000 per month. Then, Goldman Sachs analyst Jim Schneider shares his reaction to Nvidia's latest earnings report that has the stock jumping. Plus, Synopsys CEO Sassine Ghazi joins on the heels of a beat and raise.
Squawk on the Street Disclaimer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.